<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01651598</url>
  </required_header>
  <id_info>
    <org_study_id>1313.2</org_study_id>
    <secondary_id>2012-001615-23</secondary_id>
    <nct_id>NCT01651598</nct_id>
  </id_info>
  <brief_title>Multiple Rising Dose Study of BI 144807 Powder in Bottle in Mild Asthmatic Patients</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics, and Exploratory Pharmacodynamics of Multiple Rising Doses of BI 144807 Powder for Oral Drinking Solution Over a Period of 14 Days in Otherwise Healthy Controlled Asthmatic Subjects in a Randomised, Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      In this trial the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of
      multiple dose administration of BI 144807 will be investigated in otherwise healthy,
      controlled asthmatic patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number (% patients) of drug-related adverse events</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma after first dose (Cmax)</measure>
    <time_frame>up to 24 hours after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma after last dose (Cmax,ss)</measure>
    <time_frame>up to 72 hours after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from first dosing to maximum measured concentration (Tmax)</measure>
    <time_frame>up to 24 hours after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from last dosing to maximum measured concentration (Tmax,ss)</measure>
    <time_frame>up to 72 hours after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from t1 to t2 after administration of the first dose (AUCt1-t2)</measure>
    <time_frame>up to 24 hours after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t (AUCt,ss)</measure>
    <time_frame>up to 72 hours after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life of the analyte in plasma after the first dose (t1/2)</measure>
    <time_frame>up to 24 hours after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life of the analyte in plasma at steady state (t1/2,ss)</measure>
    <time_frame>up to 72 hours after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RA,Cmax (Accumulation ratio of the analyte in plasma at steady state after multiple oral administration over a uniform dosing interval τ, expressed as ratio of Cmax at steady state and after single dose)</measure>
    <time_frame>up to 72 hours after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RA,AUC (Accumulation ratio of the analyte in plasma at steady state after multiple oral administration over a uniform dosing interval τ, expressed as ratio of AUC at steady state and after single dose)</measure>
    <time_frame>up to 72 hours after last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Healthy</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>BI 144807</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive multiple BID doses of BI 144807 solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects receive multiple BID doses of Placebo solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BI 144807</intervention_name>
    <description>multiple dose (bid)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 144807</intervention_name>
    <description>multiple dose (bid, low to high dose)</description>
    <arm_group_label>BI 144807</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. mild asthmatic, otherwise healthy subjects (male and female of non-childbearing
        potential)

        Exclusion criteria:

        1. Apart from mild asthma any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1313.2.44001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2012</study_first_submitted>
  <study_first_submitted_qc>July 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2012</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

